Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1990 August; 86(2): 444–452.
PMCID: PMC296746

Paradoxical expression of adenosine deaminase in T cells cultured from a patient with adenosine deaminase deficiency and combine immunodeficiency.


T lymphocytes cultured from a patient (T.D.) with adenosine deaminase (ADA) deficiency expressed ADA activity in the normal range, inconsistent with her severe immunodeficiency, metabolic abnormalities, and with the absence of ADA activity in her B lymphocytes and other nucleated hematopoietic cells. ADA from T.D. T cells had normal Km, heat stability, and sensitivity to ADA inhibitors. Examination of HLA phenotype and polymorphic DNA loci indicated that T.D. was neither chimeric nor a genetic mosaic. Amplified and subcloned ADA cDNA from ADA+ T.D. T cells was shown by allele-specific oligonucleotide hybridization to possess the same mutations (Arg101----Trp, Arg211----His) previously found in the ADA-T.D. B cell line GM 2606 (Akeson, A. L., D. A. Wiginton, M. R. Dusing, J. C. States, and J. J. Hutton. 1988. J. Biol. Chem. 263:16291-16296). Our findings suggest that one of these mutant alleles can be expressed selectively in IL-2-dependent T cells as stable, active enzyme. Cultured T cells from other patients with the Arg211----His mutation did not express significant ADA activity, while some B cell lines from a patient with an Arg101----Gln mutation have been found to express normal ADA activity. We speculate that Arg101 may be at a site that determines degradation of ADA by a protease that is under negative control by IL-2 in T cells, and is variably expressed in B cells. Il-2 might increase ADA expression in T cells of patients who possess mutations of Arg101.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.9M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972 Nov 18;2(7786):1067–1069. [PubMed]
  • Hirschhorn R. Inherited enzyme deficiencies and immunodeficiency: adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficiencies. Clin Immunol Immunopathol. 1986 Jul;40(1):157–165. [PubMed]
  • Jenkins T. Red-blood-cell adenosine deaminase deficiency in a "healthy" Kung individual. Lancet. 1973 Sep 29;2(7831):736–736. [PubMed]
  • Jenkins T, Rabson AR, Nurse GT, Lane AB. Deficiency of adenosine deaminase not associated with severe combined immunodeficiency. J Pediatr. 1976 Nov;89(5):732–736. [PubMed]
  • Hirschhorn R, Roegner V, Jenkins T, Seaman C, Piomelli S, Borkowsky W. Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme. J Clin Invest. 1979 Oct;64(4):1130–1139. [PMC free article] [PubMed]
  • Borkowsky W, Gershon AA, Shenkman L, Hirschhorn R. Adenosine deaminase deficiency without immunodeficiency: clinical and metabolic studies. Pediatr Res. 1980 Jul;14(7):885–889. [PubMed]
  • Hirschhorn R, Martiniuk F, Roegner-Maniscalco V, Ellenbogen A, Perignon JL, Jenkins T. Genetic heterogeneity in partial adenosine deaminase deficiency. J Clin Invest. 1983 Jun;71(6):1887–1892. [PMC free article] [PubMed]
  • Daddona PE, Mitchell BS, Meuwissen HJ, Davidson BL, Wilson JM, Koller CA. Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation. J Clin Invest. 1983 Aug;72(2):483–492. [PMC free article] [PubMed]
  • Schmalstieg FC, Mills GC, Tsuda H, Goldman AS. Severe combined immunodeficiency in a child with a healthy adenosine deaminase deficient mother. Pediatr Res. 1983 Dec;17(12):935–940. [PubMed]
  • Hirschhorn R, Ellenbogen A. Genetic heterogeneity in adenosine deaminase (ADA) deficiency: five different mutations in five new patients with partial ADA deficiency. Am J Hum Genet. 1986 Jan;38(1):13–25. [PubMed]
  • Wiginton DA, Hutton JJ. Immunoreactive protein in adenosine deaminase deficient human lymphoblast cell lines. J Biol Chem. 1982 Mar 25;257(6):3211–3217. [PubMed]
  • Bonthron DT, Markham AF, Ginsburg D, Orkin SH. Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency. J Clin Invest. 1985 Aug;76(2):894–897. [PMC free article] [PubMed]
  • Valerio D, Dekker BM, Duyvesteyn MG, van der Voorn L, Berkvens TM, van Ormondt H, van der Eb AJ. One adenosine deaminase allele in a patient with severe combined immunodeficiency contains a point mutation abolishing enzyme activity. EMBO J. 1986 Jan;5(1):113–119. [PubMed]
  • Berkvens TM, Gerritsen EJ, Oldenburg M, Breukel C, Wijnen JT, van Ormondt H, Vossen JM, van der Eb AJ, Meera Khan P. Severe combined immune deficiency due to a homozygous 3.2-kb deletion spanning the promoter and first exon of the adenosine deaminase gene. Nucleic Acids Res. 1987 Nov 25;15(22):9365–9378. [PMC free article] [PubMed]
  • Akeson AL, Wiginton DA, States JC, Perme CM, Dusing MR, Hutton JJ. Mutations in the human adenosine deaminase gene that affect protein structure and RNA splicing. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5947–5951. [PubMed]
  • Akeson AL, Wiginton DA, Dusing MR, States JC, Hutton JJ. Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts. J Biol Chem. 1988 Nov 5;263(31):16291–16296. [PubMed]
  • Markert ML, Hutton JJ, Wiginton DA, States JC, Kaufman RE. Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements. J Clin Invest. 1988 May;81(5):1323–1327. [PMC free article] [PubMed]
  • Hirschhorn R, Tzall S, Ellenbogen A, Orkin SH. Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency. J Clin Invest. 1989 Feb;83(2):497–501. [PMC free article] [PubMed]
  • Markert ML, Norby-Slycord C, Ward FE. A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution. Am J Hum Genet. 1989 Sep;45(3):354–361. [PubMed]
  • Messner HA, Izaquirre CA, Jamal N. Identification of T lymphocytes in human mixed hemopoietic colonies. Blood. 1981 Aug;58(2):402–405. [PubMed]
  • Hakoda M, Akiyama M, Kyoizumi S, Kobuke K, Awa AA, Yamakido M. Measurement of in vivo HGPRT-deficient mutant cell frequency using a modified method for cloning human peripheral blood T-lymphocytes. Mutat Res. 1988 Jan;197(1):161–169. [PubMed]
  • Snyder FF, Mendelsohn J, Seegmiller JE. Adenosine metabolism in phytohemagglutinin-stimulated human lymphocytes. J Clin Invest. 1976 Sep;58(3):654–666. [PMC free article] [PubMed]
  • Fox IH, Andres CM, Gelfand EW, Biggar D. Purine nucleoside phosphorylase deficiency: altered kinetic properties of a mutant enzyme. Science. 1977 Sep 9;197(4308):1084–1086. [PubMed]
  • LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed]
  • Kurtzberg J, Bigner SH, Hershfield MS. Establishment of the DU.528 human lymphohemopoietic stem cell line. J Exp Med. 1985 Nov 1;162(5):1561–1578. [PMC free article] [PubMed]
  • Kurtzberg J, Waldmann TA, Davey MP, Bigner SH, Moore JO, Hershfield MS, Haynes BF. CD7+, CD4-, CD8- acute leukemia: a syndrome of malignant pluripotent lymphohematopoietic cells. Blood. 1989 Feb;73(2):381–390. [PubMed]
  • Denning SM, Kurtzberg J, Le PT, Tuck DT, Singer KH, Haynes BF. Human thymic epithelial cells directly induce activation of autologous immature thymocytes. Proc Natl Acad Sci U S A. 1988 May;85(9):3125–3129. [PubMed]
  • Doherty PJ, Huesca-Contreras M, Dosch HM, Pan S. Rapid amplification of complementary DNA from small amounts of unfractionated RNA. Anal Biochem. 1989 Feb 15;177(1):7–10. [PubMed]
  • Badley JE, Bishop GA, St John T, Frelinger JA. A simple, rapid method for the purification of poly A+ RNA. Biotechniques. 1988 Feb;6(2):114–116. [PubMed]
  • Beltz GA, Jacobs KA, Eickbush TH, Cherbas PT, Kafatos FC. Isolation of multigene families and determination of homologies by filter hybridization methods. Methods Enzymol. 1983;100:266–285. [PubMed]
  • Angelini G, de Preval C, Gorski J, Mach B. High-resolution analysis of the human HLA-DR polymorphism by hybridization with sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4489–4493. [PubMed]
  • Wiginton DA, Adrian GS, Friedman RL, Suttle DP, Hutton JJ. Cloning of cDNA sequences of human adenosine deaminase. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7481–7485. [PubMed]
  • Coulter-Karis DE, Hershfield MS. Sequence of full length cDNA for human S-adenosylhomocysteine hydrolase. Ann Hum Genet. 1989 May;53(Pt 2):169–175. [PubMed]
  • Wong Z, Wilson V, Patel I, Povey S, Jeffreys AJ. Characterization of a panel of highly variable minisatellites cloned from human DNA. Ann Hum Genet. 1987 Oct;51(Pt 4):269–288. [PubMed]
  • Cohen A, Hirschhorn R, Horowitz SD, Rubinstein A, Polmar SH, Hong R, Martin DW., Jr Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978 Jan;75(1):472–476. [PubMed]
  • Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987 Mar 5;316(10):589–596. [PubMed]
  • Markert ML, Hershfield MS, Schiff RI, Buckley RH. Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients. J Clin Immunol. 1987 Sep;7(5):389–399. [PubMed]
  • Rubinstein A, Hirschhorn R, Sicklick M, Murphy RA. In vivo and in vitro effects of thymosin and adenosine deaminase on adenosine-deaminase-deficient lymphocytes. N Engl J Med. 1979 Feb 22;300(8):387–392. [PubMed]
  • Daddona PE, Kelley WN. Characteristics of an aminohydrolase distinct from adenosine deaminase in cultured human lymphoblasts. Biochim Biophys Acta. 1981 Apr 14;658(2):280–290. [PubMed]
  • Schrader WP, Pollara B, Meuwissen HJ. Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978 Jan;75(1):446–450. [PubMed]
  • Hershfield MS, Francke U. The human genes for S-adenosylhomocysteine hydrolase and adenosine deaminase are syntenic on chromosome 20. Science. 1982 May 14;216(4547):739–742. [PubMed]
  • Mohandas T, Sparkes RS, Suh EJ, Hershfield MS. Regional localization of the human genes for S-adenosylhomocysteine hydrolase (cen----q131) and adenosine deaminase (q131----qter) on chromosome 20. Hum Genet. 1984;66(4):292–295. [PubMed]
  • Daddona PE, Shewach DS, Kelley WN, Argos P, Markham AF, Orkin SH. Human adenosine deaminase. cDNA and complete primary amino acid sequence. J Biol Chem. 1984 Oct 10;259(19):12101–12106. [PubMed]
  • Adrian GS, Wiginton DA, Hutton JJ. Characterization of normal and mutant adenosine deaminase messenger RNAs by translation and hybridization to a cDNA probe. Hum Genet. 1984;68(2):169–172. [PubMed]
  • Adrian GS, Hutton JJ. Adenosine deaminase messenger RNAs in lymphoblast cell lines derived from leukemic patients and patients with hereditary adenosine deaminase deficiency. J Clin Invest. 1983 Jun;71(6):1649–1660. [PMC free article] [PubMed]
  • Uberti J, Lightbody JJ, Wolf JW, Anderson JA, Reid RH, Johnson RM. The effect of adenosine on mitogenesis of ADA-deficient lymphocytes. Clin Immunol Immunopathol. 1978 Aug;10(4):446–458. [PubMed]
  • Uberti J, Peterson WD, Jr, Lightbody JJ, Johnson RM. A phenotypically normal revertant of an adenosine deaminase-deficient lymphoblast cell line. J Immunol. 1983 Jun;130(6):2866–2870. [PubMed]
  • Daddona PE, Frohman MA, Kelley WN. Human adenosine deaminase and its binding protein in normal and adenosine deaminase-deficient fibroblast cell strains. J Biol Chem. 1980 Jun 25;255(12):5681–5687. [PubMed]
  • Ruers TJ, Buurman WA, van der Linden CJ. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells. J Immunol. 1987 Jan 1;138(1):116–122. [PubMed]
  • Cowan MJ, Smith W, Ammann AJ. Interleukin 2 responsive lymphocytes in patients with adenosine deaminase deficiency. Clin Immunol Immunopathol. 1989 Oct;53(1):59–67. [PubMed]
  • Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH, Scudiery D, Berger M, Sorensen RU. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr. 1988 Aug;113(2):312–317. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation